Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Browse by Current Cardiff authors

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Number of items: 32.

AlAmri, Mubarak A., Jeeves, Mark and Mehellou, Youcef 2019. Sequence specific assignment and determination of OSR1 C-terminal domain structure by NMR. Biochemical and Biophysical Research Communications 512 (2) , pp. 338-343. 10.1016/j.bbrc.2019.03.065
Item availability restricted.
file

Miccoli, Ageo, Dhiani, Binar and Mehellou, Youcef 2019. Phosphotyrosine prodrugs: design, synthesis and anti-STAT3 activity of ISS-610 aryloxy triester phosphoramidate prodrugs. MedChemComm 10 (2) , pp. 200-208. 10.1039/C8MD00244D
Item availability restricted.
file

Alanazi, Ashwag S., James, Edward and Mehellou, Youcef 2019. The protide prodrug technology: Where next? ACS Medicinal Chemistry Letters 10 (1) , pp. 2-5. 10.1021/acsmedchemlett.8b00586
Item availability restricted.
file

Lambourne, Olivia A. and Mehellou, Youcef 2018. Chemical strategies for activating PINK1, a protein kinase mutated in Parkinson's Disease. ChemBioChem 19 (23) , pp. 2433-2437. 10.1002/cbic.201800497
file

AlAmri, Mubarak A, Kadri, Hachemi, Jeeves, Mark, Alderwick, Luke J and Mehellou, Youcef 2018. The photosensitizing clinical agent verteporfin is an inhibitor of SPAK and OSR1 kinases. ChemBioChem 19 (19) , pp. 2072-2080. 10.1002/cbic.201800272
file

Mehellou, Youcef, Alamri, Mubarak A., Dhiani, Binar A. and Kadri, Hachemi 2018. C -terminal phosphorylation of SPAK and OSR1 kinases promotes their binding and activation by the scaffolding protein MO25. Biochemical and Biophysical Research Communications 503 (3) , pp. 1868-1873. 10.1016/j.bbrc.2018.07.128
file

Kadri, Hachemi, Lambourne, Olivia A and Mehellou, Youcef 2018. Niclosamide, a drug with many (re)purposes. ChemMedChem 13 (11) , pp. 1088-1091. 10.1002/cmdc.201800100
file

Mehellou, Youcef, Rattan, Hardeep S. and Balzarini, Jan 2018. The ProTide prodrug technology: from the concept to the clinic. Journal of Medicinal Chemistry 61 (6) , pp. 2211-2226. 10.1021/acs.jmedchem.7b00734
file

Davey, Martin S., Malde, Roshni, Mykura, Rory C., Baker, Alfie T., Taher, Taher E., Le Duff, Cécile S., Willcox, Benjamin E. and Mehellou, Youcef 2018. Synthesis and biological evaluation of (E)-4-hydroxy-3-methylbut2-enyl phosphate (HMBP) aryloxy triester phosphoramidate Prdrugs as activators of Vγ9/Vδ2 T-cells immune response. Journal of Medicinal Chemistry 61 (5) , pp. 2111-2117. 10.1021/acs.jmedchem.7b01824
file

Barini, Erica, Miccoli, Ageo, Tinarelli, Federico, Mulholand, Katie, Kadri, Hachemi, Khanim, Farhat, Stojanovski, Laste, Read, Kevin D, Burness, Kerry, Blow, Julian J, Mehellou, Youcef and Muqit, Miratul 2018. The anthelmintic drug niclosamide and its analogues activate the Parkinson's Disease associated protein kinase PINK1. Chembiochem 19 (5) , pp. 425-429. 10.1002/cbic.201700500
file

Salim, Mahboob, Knowles, Timothy J., Baker, Alfie T., Davey, Martin S., Jeeves, Mark, Sridhar, Pooja, Wilkie, John, Willcox, Carrie R., Kadri, Hachemi, Taher, Taher E, Vantourout, Pierre, Hayday, Adrian, Mehellou, Youcef, Mohammed, Fiyaz and Willcox, Benjamin E. 2017. BTN3A1 discriminates γδ T cell phosphoantigens from non-antigenic small molecules via a conformational sensor in its B30.2 domain. ACS Chemical Biology 12 (10) , pp. 2631-2643. 10.1021/acschembio.7b00694
file

AlAmri, Mubarak A., Kadri, Hachemi, Dhiani, Binar Asrining, Mahmood, Shumail, Elzwawi, Abdulrahman and Mehellou, Youcef 2017. WNK-signaling inhibitors as potential new antihypertensive drugs. Chemmedchem 10.1002/cmdc.201700425
file

Alamri, Mubarak A, Kadri, Hachemi, Alderwick, Luke J, Simpkins, Nigel S and Mehellou, Youcef 2017. Rafoxanide and Closantel inhibit SPAK and OSR1 kinases by binding to a highly conserved allosteric site on their C-terminal domains. ChemMedChem 12 (9) , pp. 639-645. 10.1002/cmdc.201700077
file

Osgerby, Laura, Lai, Yu-Chiang, Thornton, Peter J., Amalfitano, Joseph, Le Duff, Cécile S., Jabeen, Iqra, Kadri, Hachemi, Miccoli, Ageo, Tucker, James H. R., Muqit, Miratul M. K. and Mehellou, Youcef 2017. Kinetin riboside and its ProTides activate the Parkinson's Disease associated PTEN-Induced Putative Kinase 1 (PINK1) independent of mitochondrial depolarization. Journal of Medicinal Chemistry 60 (8) , pp. 3518-3524. 10.1021/acs.jmedchem.6b01897
file

Kadri, Hachemi, AlAmri, Mubarak A, Navratilova, Iva H, Alderwick, Luke J, Simpkins, Nigel S and Mehellou, Youcef 2017. Towards the development of small molecule MO25-binders as potential indirect SPAK/OSR1 kinase inhibitors. Chembiochem 18 (5) , pp. 460-465. 10.1002/cbic.201600620
file

Kedge, Jonathan L., Nguyen, Huy V., Khan, Zahra, Male, Louise, Hodges, Media K. Ismail Holly V. Roberts Ni, Horswell, Sarah L., Mehellou, Youcef and Tucker, James H. R. 2017. Organometallic nucleoside analogues: effect of hydroxyalkyl linker length on cancer cell line toxicity. European Journal of Inorganic Chemistry 2017 (2) , pp. 466-476. 10.1002/ejic.201600853
file

Thornton, Peter J., Kadri, Hachemi, Miccoli, Ageo and Mehellou, Youcef 2016. Nucleoside phosphate and phosphonate prodrug clinical candidates. Journal of Medicinal Chemistry 59 (23) , pp. 10400-10410. 10.1021/acs.jmedchem.6b00523
file

Mehellou, Youcef 2016. The ProTides boom. Chemmedchem 11 (11) , pp. 1114-1116. 10.1002/cmdc.201600156
file

Nguyen, Huy V., Sallustrau, Antoine, Balzarini, Jan, Bedford, Matthew R., Eden, John C., Georgousi, Niki, Hodges, Nikolas J., Kedge, Jonathan, Mehellou, Youcef, Tselepis, Chris and Tucker, James H. R. 2014. Organometallic nucleoside analogues with ferrocenyl linker groups: Synthesis and cancer cell line studies. Journal of Medicinal Chemistry 57 (13) , pp. 5817-5822. 10.1021/jm500246h
file

Ohta, Akihito, Schumacher, Frances-Rose, Mehellou, Youcef, Johnson, Clare, Knebel, Axel, Macartney, Thomas J., Wood, Nicola T., Alessi, Dario R. and Kurz, Thimo 2013. The CUL3–KLHL3 E3 ligase complex mutated in Gordon's hypertension syndrome interacts with and ubiquitylates WNK isoforms: disease-causing mutations in KLHL3 and WNK4 disrupt interaction. Biochemical Journal 451 (1) , pp. 111-122. 10.1042/BJ20121903
file

Mehellou, Youcef, Alessi, Dario R., Macartney, Thomas J., Szklarz, Marta, Knapp, Stefan and Elkins, Jonathan M. 2013. Structural insights into the activation of MST3 by MO25. Biochemical and Biophysical Research Communications 431 (3) , pp. 604-609. 10.1016/j.bbrc.2012.12.113
file

Chen, Shengxi, Fahmi, Nour Eddine, Nangreave, Ryan C., Mehellou, Youcef and Hecht, Sidney M. 2012. Synthesis of pdCpAs and transfer RNAs activated with thiothreonine and derivatives. Bioorganic & Medicinal Chemistry 20 (8) , pp. 2679-2689. 10.1016/j.bmc.2012.02.024

Thastrup, Jacob O., Rafiqi, Fatema H., Vitari, Alberto C., Pozo-Guisado, Eulalia, Deak, Maria, Mehellou, Youcef and Alessi, Dario R. 2012. SPAK/OSR1 regulate NKCC1 and WNK activity: analysis of WNK isoform interactions and activation by T-loop trans-autophosphorylation. Biochemical Journal 441 (1) , pp. 325-337. 10.1042/BJ20111879
file

Filippi, Beatrice M., de los Heros, Paola, Mehellou, Youcef, Navratilova, Iva, Gourlay, Robert, Deak, Maria, Plater, Lorna, Toth, Rachel, Zeqiraj, Elton and Alessi, Dario R. 2011. MO25 is a master regulator of SPAK/OSR1 and MST3/MST4/YSK1 protein kinases. EMBO Journal 30 (9) , pp. 1730-1741. 10.1038/emboj.2011.78

Mehellou, Youcef 2010. Phosphoramidate Prodrugs Deliver with Potency Against Hepatitis C Virus. ChemMedChem 5 (11) , pp. 1841-1842. 10.1002/cmdc.201000310

Mehellou, Youcef, Valente, Rocco, Mottram, Huw James, Walsby, Elisabeth Jane, Mills, Kenneth Ian, Balzarini, Jan and McGuigan, Christopher 2010. Phosphoramidates of 2′-β-d-arabinouridine (AraU) as phosphate prodrugs; design, synthesis, in vitro activity and metabolism. Bioorganic & Medicinal Chemistry 18 (7) , pp. 2439-2446. 10.1016/j.bmc.2010.02.059

Mehellou, Youcef, Balzarini, Jan and McGuigan, Christopher 2010. The design, synthesis and antiviral evaluation of a series of 5-trimethylsilyl-1-β-D-(arabinofuranosyl)uracil phosphoramidate ProTides. Antiviral Chemistry & Chemotherapy 20 (4) , pp. 153-160. 10.3851/IMP1476

Mehellou, Youcef and De Clercq, Erik 2010. Twenty-Six Years of Anti-HIV Drug Discovery: Where Do We Stand and Where Do We Go? Journal of Medicinal Chemistry 53 (2) , pp. 521-538. 10.1021/jm900492g

Mehellou, Youcef, Balzarini, J. and McGuigan, Christopher 2009. An investigation into the anti-HIV activity of 2 ',3 '-didehydro-2 ',3 '-dideoxyuridine (d4U) and 2 ',3 '-dideoxyuridine (ddU) phosphoramidate 'ProTide' derivatives. Organic and Biomolecular Chemistry 7 (12) , pp. 2548-2553. 10.1039/b904276h

Mehellou, Youcef, Balzarini, J. and McGuigan, Christopher 2009. Aryloxy Phosphoramidate Triesters: a Technology for Delivering Monophosphorylated Nucleosides and Sugars into Cells. Chemmedchem 4 (11) , pp. 1779-1791. 10.1002/cmdc.200900289

Mehellou, Youcef, McGuigan, Christopher, Brancale, Andrea and Balzarini, J. 2007. Design, synthesis, and anti-HIV activity of 2',3'-didehydro-2',3'-dideoxyuridine (d4U), 2',3'-dideoxyuridine (ddU) phosphoramidate "ProTide' derivatives. Biorganic and Medicinal Chemistry Letters 17 (13) , pp. 3666-3669. 10.1016/j.bmcl.2007.04.043

Mehellou, Youcef, McGuigan, Christopher and Balzarini, J. 2007. The design, synthesis and Anti-HIV activity of a selected group of 2 ',3 '-didehydro-2 ',3 '-dideoxyguanosine (d4G) and 2 ',3 '-dideoxyguanosine (ddG) 'ProTide' derivatives. Antiviral Research 74 (3) , 50. 10.1016/j.antiviral.2007.01.063

This list was generated on Wed Oct 16 05:03:30 2019 BST.